Henry F. McFarland, MD
Affiliations: | NINDS / Neuroimmunology Branch | National Institutes of Health, Bethesda, MD |
Area:
multiple sclerosis, neuroimmunology,MR imagingGoogle:
"Henry McFarland"Mean distance: 20.48 (cluster 46)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Suto DJ, Nair G, Sudarshana DM, et al. (2020) Manganese-Enhanced MRI in Patients with Multiple Sclerosis. Ajnr. American Journal of Neuroradiology. 41: 1569-1576 |
| Neil S, Huh J, Baronas V, et al. (2017) Oral administration of the nitroxide radical TEMPOL exhibits immunomodulatory and therapeutic properties in multiple sclerosis models. Brain, Behavior, and Immunity |
| Sati P, Oh J, Constable RT, et al. (2016) The central vein sign and its clinical evaluation for the diagnosis of multiple sclerosis: a consensus statement from the North American Imaging in Multiple Sclerosis Cooperative. Nature Reviews. Neurology |
| Stone LA, Cutter GR, Fisher E, et al. (2015) Relapse May Serve as a Mediator Variable in Longitudinal Outcomes in Multiple Sclerosis. Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging |
| Borges IT, Shea CD, Ohayon J, et al. (2013) The effect of daclizumab on brain atrophy in relapsing-remitting multiple sclerosis. Multiple Sclerosis and Related Disorders. 2: 133-140 |
| Yuen TJ, Johnson KR, Miron VE, et al. (2013) Identification of endothelin 2 as an inflammatory factor that promotes central nervous system remyelination. Brain : a Journal of Neurology. 136: 1035-47 |
| Ohayon J, Oh U, Richert N, et al. (2013) CNS vasculitis in a patient with MS on daclizumab monotherapy. Neurology. 80: 453-7 |
| Quandt JA, Huh J, Baig M, et al. (2012) Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. Journal of Immunology (Baltimore, Md. : 1950). 189: 2897-908 |
| Bielekova B, Richert N, Herman ML, et al. (2011) Intrathecal effects of daclizumab treatment of multiple sclerosis Neurology. 77: 1877-1886 |
| McFarland H. (2011) The importance of clinical trials in unraveling the mysteries of multiple sclerosis Journal of Neuroimmunology. 231: 3-6 |